Randomized Trial of Contrast Media Utilization in High-Risk PTCA
| Autor: | Charles J. Davidson, Dean J. Kereiakes, James B. Hermiller, Joseph B. Muhlestein, Ronald E. Vlietstra, John W. Hirshfeld, Jeffrey A. Brinker, Maurice Buchbinder, Alexandra J. Lansky, Jeffrey J. Popma, William H. Matthai, Warren K. Laskey, J. Kevin Harrison |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Contrast Media Coronary Disease Court trial law.invention Double-Blind Method Randomized controlled trial law Triiodobenzoic Acids Physiology (medical) Angioplasty Internal medicine Ioxaglic Acid medicine Clinical endpoint Humans Myocardial infarction Angioplasty Balloon Coronary Aged business.industry Middle Aged medicine.disease Iodixanol Treatment Outcome medicine.anatomical_structure Cardiology Female Cardiology and Cardiovascular Medicine business Mace Artery medicine.drug |
| Zdroj: | Circulation. 101:2172-2177 |
| ISSN: | 1524-4539 0009-7322 |
| DOI: | 10.1161/01.cir.101.18.2172 |
| Popis: | Background —Previous in vitro and in vivo studies have suggested an association between thrombus-related events and type of contrast media. Low osmolar contrast agents appear to improve the safety of diagnostic and coronary artery interventional procedures. However, no data are available on PTCA outcomes with an isosmolar contrast agent. Methods and Results —A multicenter prospective randomized double-blind trial was performed in 856 high-risk patients undergoing coronary artery intervention. The objective was to compare the isosmolar nonionic dimer iodixanol (n=405) with the low osmolar ionic agent ioxaglate (n=410). A composite variable of in-hospital major adverse clinical events (MACE) was the primary end point. A secondary objective was to evaluate major angiographic and procedural events during and after PTCA. The composite in-hospital primary end point was less frequent in those receiving iodixanol compared with those receiving ioxaglate (5.4% versus 9.5%, respectively; P =0.027). Core laboratory defined angiographic success was more frequent in patients receiving iodixanol (92.2% versus 85.9% for ioxaglate, P =0.004). There was a trend toward lower total clinical events at 30 days in patients randomized to iodixanol (9.1% versus 13.2% for ioxaglate, P =0.07). Multivariate predictors of in-hospital MACE were use of ioxaglate ( P =0.01) and treatment of a de novo lesion ( P =0.03). Conclusions —In this contemporary prospective multicenter trial of PTCA in the setting of acute coronary syndromes, there was a low incidence of in-hospital clinical events for both treatment groups. The cohort receiving the nonionic dimer iodixanol experienced a 45% reduction in in-hospital MACE when compared with the cohort receiving ioxaglate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|